Celsion Corporation (now Imunon, Inc.) — Q1 2016 Form 10-Q
Reporting period: Three months ended March 31, 2016; filed May 16, 2016. The filing identifies the registrant as Celsion Corporation. Financial statements are unaudited.
Business context
Celsion was a clinical-stage oncology drug developer with no material product sales. Its lead candidate, ThermoDox, was in Phase III development for primary liver cancer and Phase II testing for recurrent chest-wall breast cancer. The company was also developing GEN-1, an early-stage DNA-based immunotherapy, and acquired TheraPlas and TheraSilence platforms.
Financial performance and liquidity
| Metric | Q1 2016 | Q1 2015 / comparison |
|---|---|---|
| Licensing revenue | $125,000 | $125,000 |
| Research and development expense | $3.44 million | $4.51 million; down 23.6% |
| General and administrative expense | $1.86 million | $2.03 million; down 8.3% |
| Total operating expenses | $5.30 million | $6.54 million; down 18.9% |
| Operating loss | $5.18 million | $6.41 million |
| Net loss | $5.72 million | $7.01 million |
| Basic and diluted loss per share | $0.24 | $0.35 |
| Cash used in operating activities | $4.74 million | $5.94 million |
The smaller net loss reflected lower operating expenses and interest expense, partly offset by a larger noncash charge for the EGEN earn-out liability. Revenue was limited to amortization of a previously received Hisun payment; the filing reports no meaningful product revenue. Gross margin is not a useful measure for this development-stage business.
Cash and cash equivalents were $14.31 million at March 31, 2016, compared with $9.27 million at year-end. The increase largely reflected $10.80 million of proceeds from selling or collecting investments previously classified as short-term investments; it was not generated by operations. Current assets were $14.68 million and current liabilities $9.56 million, for working capital of approximately $5.12 million, down from $10.96 million at December 31, 2015.
Notes payable had a carrying value of $5.52 million, with $5.36 million principal outstanding. The secured Hercules loan bore 11.50% interest and was scheduled to mature June 1, 2017. The company paid approximately $0.99 million of principal in the quarter. It reported an accumulated deficit of $224.0 million and stockholders’ equity of $15.3 million.
Changes, outlook, and key risks
- R&D spending declined, including lower ThermoDox manufacturing costs and GEN-1 spending. OPTIMA-related costs were approximately $1.0 million in Q1 2016. G&A was broadly stable.
- Management estimated that cash on hand together with access to its at-the-market equity facility would fund operations through Q1 2017. This was not a guarantee: the company expected substantial continuing losses, had no other committed financing, and said additional capital would be needed. Equity financing could dilute shareholders; insufficient funding could force reduced or delayed programs.
- The filing states $17.4 million remained under the overall ATM agreement, while a prospectus supplement registered up to $7.5 million for sales under the facility. Confirm the amount then legally available to sell.
- ThermoDox had previously failed the primary progression-free-survival endpoint in the Phase III HEAT study. Management cited a favorable post-hoc overall-survival subgroup analysis as support for the separate Phase III OPTIMA trial; those retrospective findings are not confirmation of efficacy. The company expected OPTIMA enrollment to finish in Q1 2018. The first Chinese patient was enrolled on April 26, 2016, after quarter-end.
- GEN-1’s OVATION study remained early stage. The company reported preliminary first-cohort results on May 2, 2016, after quarter-end; the small cohort’s observations are not definitive evidence of efficacy or safety.
- The EGEN acquisition created up to $30.4 million in contingent milestone payments. The recorded earn-out liability rose to $14.22 million, producing a $302,656 noncash expense in Q1. Payment depends on specified development milestones and may be made in cash, shares, or both.
- Other material risks include clinical-trial failure or delay, regulatory and manufacturing hurdles, dependence on outside clinical and manufacturing partners, intellectual-property and licensing risks, potential asset impairment, dilution, and Nasdaq listing compliance. The filing reported no legal proceedings and no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether the $7.5 million registered ATM capacity was available in addition to, or represented part of, the stated $17.4 million remaining facility capacity, and actual subsequent ATM sales.
- Cash use and financing needs relative to management’s Q1 2017 runway estimate, including clinical-trial costs and debt payments.
- OPTIMA enrollment pace, trial design and interim-monitoring status, and whether later results validate the post-hoc HEAT subgroup analysis.
- Subsequent GEN-1 clinical data, noting the limited size and early stage of the reported cohort.
- Potential dilution from outstanding warrants, options, equity awards, ATM issuance, and any EGEN milestone shares; the filing reported 5.89 million warrants outstanding at March 31, 2016.